regenerative medicine Archives

How NewcelX Ltd. is pursuing durable islet graft survival in the race for a functional diabetes cure

How NewcelX Ltd. is advancing NCEL-101 toward a functional diabetes cure through durable islet graft survival and immune protection strategies.

iPSC demand is rising fast. FUJIFILM’s Madison facility tests whether stem cell manufacturing can keep pace with pharma and cell therapy needs.

Beauty wants biotech credibility. AVL’s IVF-inspired skincare push tests whether longevity science can reshape premium skincare.

Cell therapy scale-up is not just a science problem. Charles River and MEDIPOST are targeting the GMP testing bottleneck.

MSC science is advancing faster than manufacturing can scale. Terumo BCT and Steminent are testing whether automation can close that gap.

Novo shelved the asset, but Cellular Intelligence sees a platform test. Parkinson’s cell therapy now faces its harder commercial trial.

ACL surgery needs better graft choices. CoreTissue BioEngineering’s CT-ACL001 now faces the harder randomized test.

Cryo-Cell avoided immediate delisting pressure. The harder test is whether its cord blood banking model can repair the balance sheet by 2027.

Discover how BioCardia, Inc.’s Heart3D platform could reduce variability in cardiac cell therapy. Read the full analysis on what this means next.

New exosome therapy targets spinal cord injury repair non-invasively. Find out how this breakthrough could reshape neuroregenerative medicine.